These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Stability of ursodiol in an extemporaneously compounded oral liquid. Johnson CE; Nesbitt J Am J Health Syst Pharm; 1995 Aug; 52(16):1798-1800. PubMed ID: 8528836 [TBL] [Abstract][Full Text] [Related]
9. Stability of gabapentin in extemporaneously compounded oral suspensions. Friciu M; Roullin VG; Leclair G PLoS One; 2017; 12(4):e0175208. PubMed ID: 28414771 [TBL] [Abstract][Full Text] [Related]
10. Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF. Geiger CM; Sorenson B; Whaley P Int J Pharm Compd; 2015; 19(5):420-7. PubMed ID: 26775449 [TBL] [Abstract][Full Text] [Related]
11. Stability and uniformity of extemporaneous preparations of voriconazole in two liquid suspension vehicles at two storage temperatures. Nguyen KQ; Hawkins MG; Taylor IT; Wiebe VJ; Tell LA Am J Vet Res; 2009 Jul; 70(7):908-14. PubMed ID: 19566477 [TBL] [Abstract][Full Text] [Related]
12. Long-term Stability of a Compounded Suspension of Torsemide (5 mg/mL) for Oral Administration. Adin D; Johnson PR; Kim CH; Nguyenba T; Rosen S J Vet Intern Med; 2017 Nov; 31(6):1822-1826. PubMed ID: 28913839 [TBL] [Abstract][Full Text] [Related]
13. Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4. Polonini H; da Silva SL; Cunha CN; Ferreira AO; Anagnostou K; Dijkers E Int J Pharm Compd; 2020; 24(3):252-262. PubMed ID: 32401746 [TBL] [Abstract][Full Text] [Related]
14. Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend SF PH4 oral suspensions. Polonini HC; Silva SL; Cunha CN; Brandão MA; Ferreira AO Pharmazie; 2016 Apr; 71(4):185-91. PubMed ID: 27209697 [TBL] [Abstract][Full Text] [Related]
15. Stability of procainamide hydrochloride in an extemporaneously compounded oral liquid. Metras JI; Swenson CF; McDermott MP Am J Hosp Pharm; 1992 Jul; 49(7):1720-4. PubMed ID: 1621730 [TBL] [Abstract][Full Text] [Related]
16. Stability of isradipine in an extemporaneously compounded oral liquid. MacDonald JL; Johnson CE; Jacobson P Am J Hosp Pharm; 1994 Oct; 51(19):2409-11. PubMed ID: 7847406 [TBL] [Abstract][Full Text] [Related]
17. Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4. Polonini H; da Silva SL; Brandão MAF; Bauters T; De Moerloose B; Ferreira AO Int J Pharm Compd; 2018; 22(6):516-526. PubMed ID: 30384353 [TBL] [Abstract][Full Text] [Related]
18. Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4. Espana B; Joseph-Tornabène F; Jaquet C; Perrot S; Prouillac C Int J Pharm Compd; 2020; 24(4):327-336. PubMed ID: 32649306 [TBL] [Abstract][Full Text] [Related]
19. Stability of flucytosine in an extemporaneously compounded oral liquid. Wintermeyer SM; Nahata MC Am J Health Syst Pharm; 1996 Feb; 53(4):407-9. PubMed ID: 8673661 [TBL] [Abstract][Full Text] [Related]
20. The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment. Meissner S; Bansal M; Dela CPD; Hanning S; Svirskis D Int J Pharm Compd; 2020; 24(2):140-147. PubMed ID: 32196476 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]